Alper / Koenig Line: Ibogaine–hERG Cardiac Mechanism — Preclinical / Mechanistic (Not Human Efficacy)

Definition box

Definition: This paper-spoke summarizes preclinical/mechanistic evidence that iboga alkaloids inhibit cardiac hERG (human Ether-à-go-go–Related Gene; Kv11.1) potassium channels that carry IKr, delaying ventricular repolarization—the cellular rationale linking ibogaine/noribogaine to QT/QTc prolongation and torsades risk. A primary citable human-cell electrophysiology report is **Alper K. et al., “hERG Blockade by Iboga Alkaloids,” *Cardiovascular Toxicology* (2016;16(1):14–22; doi: 10.1007/s12012-015-9311-5; PMID 25636206), measuring IKr IC50 values in the low-micromolar range for ibogaine and noribogaine (and related alkaloids), with discussion of delayed arrhythmia timing via long-lived noribogaine. Complementary Koenig / Hilber** work (e.g., early hERG inhibition reports and *Toxicol Appl Pharmacol* ion-channel profiling) established concentration-dependent hERG block at exposures overlapping human plasma ranges after typical oral treatment doses. LABEL: PRECLINICAL / MECHANISTIC. These studies are not human efficacy RCTs, not cure evidence, and not proof of psychoactive IV ibogaine infusion. They explain *why* cardiac screening exists. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (57 words)

Alper, Koenig, and colleagues showed in cell-based electrophysiology that ibogaine and noribogaine block cardiac hERG/IKr channels at low-micromolar concentrations—mechanistic grounds for QT prolongation risk. Preclinical mechanism is not human efficacy and not proof of psychoactive IV ibogaine infusion. Schedule I; treat QTc screening as non-negotiable.

Why this paper-spoke exists

Marketing sometimes says “cardiac risk is rare, so ignore mechanism.” Mechanism is why rarity still kills. This spoke keeps hERG literacy in the SEO graph without pretending patch-clamp is a patient success story. Soft CTA: /safety-and-screening → /apply. Pair with Litjens toxicity review (/blog/litjens-brunt-2016-ibogaine-toxicity), clinical QTc (/blog/knuijver-2021-ibogaine-qtc-safety), and CV complications teaching (/blog/ibogaine-cardiovascular-complications-review).

What was studied (mechanistic cluster)

| Feature | Accurate description | |---------|----------------------| | Anchor citation | Alper K., Bai R., et al. hERG Blockade by Iboga Alkaloids. *Cardiovasc Toxicol*. 2016;16(1):14–22. doi 10.1007/s12012-015-9311-5. PMID 25636206 | | Method class | Whole-cell patch clamp / heterologously expressed hERG (HEK 293 and related systems in the broader line) | | Compounds (Alper 2016 themes) | Ibogaine (semisynthetic and plant-extracted sources), noribogaine, voacangine; contrast with 18-methoxycoronaridine (18-MC) showing much weaker functional hERG block in that report | | Example IC50 themes (Alper) | Ibogaine ~3.5–4.1 µM; noribogaine ~2.9 µM; voacangine ~2.3 µM; 18-MC >50 µM for functional block (binding affinity story more nuanced) | | Complementary line | Koenig X. et al.—ibogaine inhibits hERG; ion-channel profile work (*Toxicol Appl Pharmacol* 2013 lineage) showing low-µM hERG IC50 (~4 µM themes) overlapping human plasma ranges after typical oral doses | | Label | PRECLINICAL / MECHANISTIC — not clinical efficacy |

Methods (plain language)

Scientists put human hERG channels into cells, apply iboga alkaloids, and measure how much the potassium current shrinks. Less IKr → longer action-potential plateau → longer QT on the surface ECG in people. This is mechanism, the same class of evidence regulators use to flag QT-liable drugs—not a veteran TBI outcomes trial.

Key mechanistic findings (no hype)

• Ibogaine reduces hERG current in a concentration-dependent, reversible manner at low micromolar levels.
• Noribogaine also blocks hERG potently—critical because noribogaine’s long half-life can extend cardiac risk days after parent ibogaine falls.
• Voltage dependence consistent with low-affinity open/inactivated-state block themes appears in the alkaloid series.
• Structure–activity hints (e.g., 18-MC’s weaker functional hERG block despite binding nuances in Alper 2016) motivate analog programs—analogs are not approved consumer therapies (/blog/cameron-2020-tabernanthalog).
• Human oral treatment-dose plasma concentrations reported in older clinical PK sit in ranges that can overlap these IC50s—hence the clinical worry is not theoretical pedantry.

Honest reading: Mechanism explains risk biology. It does not quantify your personal probability and does not prove benefit.

Why SEO pages must keep saying “preclinical”

Search snippets love the phrase “scientists prove how ibogaine stops addiction.” hERG papers prove something else: how ibogaine can destabilize cardiac repolarization. Conflating those sentences is how YMYL content becomes harmful. Editorial rules for this spoke:

1. Every shareable pull-quote should include preclinical or mechanistic.
2. Every internal link path should exit to screening or clinical QTc pages, not only to hopeful MISTIC summaries.
3. Analog SAR excitement (18-MC, TBG) must deep-link with explicit “not approved therapy” labeling (/blog/cameron-2020-tabernanthalog).
4. Magnesium or telemetry protocols mitigate risk operationally—they do not rewrite IC50 physics (/blog/magnesium-ibogaine-cardiac-protocol).

If a patient only remembers one number-class from Alper 2016, let it be “low micromolar hERG block overlaps treatment-relevant exposures”—then book an ECG conversation, not a flight on impulse.

Bridge to human clinical risk

| Mechanistic claim | Clinical echo | |-------------------|---------------| | hERG/IKr ↓ | QTc ↑ on ECG | | Noribogaine persistence | Delayed events after “the trip ended” | | Low-µM potency | Flood-dose oral traditions are not casual | | Analog SAR | Research interest ≠ approved safer pill today |

Clinical spokes: /blog/knuijver-2021-ibogaine-qtc-safety, /blog/glue-2016-noribogaine-phase1, /blog/ona-2022-ibogaine-adverse-events-review.

Route honesty & entity clarity

Patch-clamp cells do not receive a branded infusion. Mechanistic hERG data inform all routes that achieve relevant plasma exposures. They especially do not prove that physician-supervised psychoactive IV ibogaine infusion is efficacious. Oral≠IV remains mandatory (/blog/ibogaine-oral-vs-iv). Entity: /what-is-ibogaine-infusion.

Limits and confounders (preclinical honesty)

| Limit | Why it matters | |-------|----------------| | In-vitro systems | Missing autonomic tone, electrolytes, polypharmacy of real patients | | IC50 ≠ individual outcome | Genetics, Mg2+, heart rate, drugs shift risk | | Not efficacy data | Zero license for cure marketing | | Analog contrasts | 18-MC/TBG interest ≠ available approved therapy | | Older PK anchors | Still directionally important; pair with newer clinical QT datasets |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “hERG paper proves treatment works” | False | | “Knowing mechanism removes need for ECG” | Dangerously false | | “Preclinical = approved IV product” | False | | Cite as mechanistic basis for QTc caution? | Yes |

LABEL REPEATED: PRECLINICAL / MECHANISTIC — NOT HUMAN EFFICACY.

Soft CTA

If mechanism talk made risk feel abstract, make it operational: /safety-and-screening → ECG/telemetry expectations → /apply only for supervised IV ibogaine infusion questions. Entity: /what-is-ibogaine-infusion.

FAQ

What did Alper et al. 2016 show? Iboga alkaloids including ibogaine and noribogaine block hERG/IKr in cell electrophysiology at low-µM IC50s (doi **10.1007/s12012-015-9311-5**).

Is this a patient outcomes trial? No—**preclinical/mechanistic**.

Why does noribogaine matter? It also blocks hERG and lasts longer—relevant to delayed QT risk.

Does hERG block prove IV ibogaine infusion efficacy? No.

Are safer analogs approved therapies? No—research compounds/programs are not FDA-approved ibogaine replacements for consumers.

Should families still demand ECG? Yes—mechanism is why (/blog/ibogaine-ecg-pre-infusion-checklist).

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Alper/Koenig hERG work is preclinical/mechanistic—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Alper K. et al. hERG Blockade by Iboga Alkaloids. *Cardiovasc Toxicol*. 2016;16(1):14–22. doi: 10.1007/s12012-015-9311-5. PMID: 25636206.
2. Koenig X. et al. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents… *Toxicol Appl Pharmacol*. 2013;273:259–268. (ion-channel profile lineage).
3. Litjens R.P.W., Brunt T.M. *Clin Toxicol*. 2016. doi: 10.3109/15563650.2016.1138226.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).